CELECOXIB

USDailyMed:Celecoxib AU:B3 L01XX33(WHO)M01AH01(WHO) AU:S4(Prescription only) or S3BR:Class C1(Other controlled substances)CA:℞-onlyNZ: Prescription onlyUK:POM(Prescription only)US:℞-onlyIn general: ℞ (Prescription only) 4-[5-(4-Methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide 169590-42-5Y 2662 2892 DB00482Y 2562Y JCX84Q7J1L D00567Y CHEBI:41423Y ChEMBL118Y CEL (PDBe,RCSB PDB) DTXSID0022777 Interactive image c1cc(C)ccc1c2cc(C(F)(F)F)nn2c3ccc(cc3)S(=O)(=O)N InChI=1S/C17H14F3N3O2S/c1-11-2-4-12(5-3-11)15-10-16(17(18,19)20)22-23(15)13-6-8-14(9-7-13)26(21,24)25/h2-10H,1H3,(H2,21,24,25)YKey:RZEKVGVHFLEQIL-UHFFFAOYSA-NY Celecoxib, sold under the brand ‍‍‍‍‍‍​​​‍​​​​​​nameCelebrexamong others, is aCOX-2 inhibitorandnonsteroidal anti-inflammatory drug(NSAID).It is used to treat thepainandinflammationinosteoarthritis,acute painin adults,rheumatoid arthritis,psoriatic arthritis,ankylosing spondylitis,painful menstruation, andjuvenile rheumatoid arthritis.It may also be used to decrease the risk ofcolorectal adenomasin people withfamilial adenomatous polyposis.It is takenby mouth.Benefits are typically seen within an hour. Common side effects includeabdominal pain, nausea, anddiarrhea.Serious side effects may includeheart attacks,strokes,gastrointestinal perforation,gastrointestinal bleeding,kidney failure, andanaphylaxis.Use is not recommended in people at high risk for heart disease.The risks are similar to other NSAIDs, such asibuprofenandnaproxen.Use in the later part ofpregnancyor duringbreastfeedingis not recommended. Celecoxib has demonstratedadjunctivebenefits inmajor depressionand efficacy in reducing polyp recurrence infamilial adenomatous polyposis, while also being investigated for broader psychiatric, anticancer, and chemopreventive applications. Celecoxib was patented in 1993 and came into medical use in 1999.It is available as ageneric medication.In 2023, it was the 111th most commonly prescribed medication in the United States, with more than 6million prescriptions.